Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02664077 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase 3 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT02664077 is a Phase 3 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 34 participants.
The verdict
NCT02664077, a Phase 3 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, post-chemotherapy, adjuvant phase III clinical trial. The primary aim of this study is to determine the value of regorafenib in improving disease-free survival (DFS). Patients with Stage III (IIIB or IIIC) colon cancer as defined by the 7th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual are randomized 1:1 to placebo or the experimental agent regorafenib following completion of at least four months of standard adjuvant therapy (e.g., 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) , capecitabine, oxaliplatin (CapeOx), and other).
Interventions
- DRUG Placebo
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02664077
The ClinicalTrials.gov registry entry for NCT02664077 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02664077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02664077 about?
NCT02664077 is a clinical study titled "A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer". This study is a randomized, double-blind, post-chemotherapy, adjuvant phase III clinical trial. The primary aim of this study is to determine the value of regorafenib in improving disease-free survival (DFS). Patients with Stage III (IIIB or IIIC) colon cancer as defined by the 7th Edition of the Am...
What is the current status of trial NCT02664077?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2016-06. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02664077?
The interventions under investigation include: Placebo (DRUG), Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02664077?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.